Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Obstetrics/Gynecology Market Research

Cervical Cancer Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030

Best Price Guarantee Length Publisher Published Date SKU
from $10,995 150 Pages GlobalData February, 2022 GBDT17058049
Best Price Guarantee
Price from $10,995
Length 150 Pages
Publisher GlobalData
Published Date February, 2022
SKU GBDT17058049

Cervical Cancer Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030

Summary

Cervical cancer is the second most common cancer in women under the age of 45: Chronic infection with high-risk oncogenic subtypes of the human papilloma virus (HPV) is the main etiological factor in cervical carcinogenesis. Surgery is the standard of care for the treatment of early-stage cervical cancer, while chemoradiation is the most common treatment modality for locally advanced disease. In the US, the approvals of Keytruda as a first line therapy and Tivdak as a second line therapy in 2021, completely altered the treatment paradigm for recurrent and distally metastatic disease. Prior to the approval of Keytruda in first line, patients received chemotherapy with Avastin, which remains the treatment of choice outside the US.

GlobalData projects the global cervical cancer market to experience substantial growth during the forecast period. Multiple checkpoint inhibitors, both used as monotherapies and in combination with other agents are forecast to either launch or expand to additional lines of therapy. The launch of an antibody drug conjugate and a tumor infiltrating lymphocyte therapy are also forecast to occur during this period. This growth will be slightly tempered by a reduction of branded sales of some agents following the introduction of generic and biosimilar alternatives.

Key Highlights

  • The main drivers of growth include the anticipated approval and launch of 13 pipeline therapies, the approval of an agent currently marketed in the US across the remaining 7MM, and the label expansion of one currently marketed therapy across the 8MM during the forecast period.
  • The main barriers to growth in the 8MM are patent expiries including those of Avastin, Keytruda, Imfinzi and Tecentriq.
  • Among the late-stage pipeline products and marketed agents, immunotherapies are expected to dominate, however Tivdak is expected to be the market leading brand.
  • The most important unmet needs in the cervical cancer market include: the need for adjuvant therapy in the locally advanced setting, the need for novel agents other than immunotherapies, the need for approval of agents outside the US market, the need for fertility-sparing treatment options, and an increase in HPV vaccine uptake.
KEY QUESTIONS ANSWERED
  • 13 late-stage pipeline agents are expected to enter the cervical cancer market from 2022 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in cervical cancer, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2020-2030? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?
Scope
  • Overview of cervical cancer including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline cervical cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting cervical cancer therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II - III).
  • Analysis of the current and future market competition in the global cervical cancer therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global cervical cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global cervical cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global cervical cancer therapeutics market from 2020-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Cervical Cancer: Executive Summary
1.1 The CC Market Will Expand to $4.8 Billion in 2030
1.2 Seagen and Genmab Expected to Take Market-Leading Position in 2030
1.3 Approval of Checkpoint Inhibitors and Tivdak Will Partially Address Significant Unmet Needs
1.4 Immunotherapy to Become Leading Therapy Class
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 8MM Forecast Methodology
4.5 Epidemiological Forecast for CC (2020-30)
4.6 Discussion
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 US
5.1.2 5EU
5.1.3 Japan
5.1.4 China
5.2 KOL Insights on Disease Management
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers - Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5 China
12.5.1 Forecast
12.5.2 Key Events
12.5.3 Drivers and Barriers
13 Appendix
List of Tables
Table 1: CC: Key Metrics in the 8MM
Table 2: Pathologic Staging of CC Using FIGO Classification
Table 3: Risk Factors and Comorbid Conditions Associated with CC
Table 4: 8MM, Diagnosed Incident Cases of CC by FIGO Stage at Diagnosis, Women, Ages ≥18 Years, N, 2020
Table 5: 8MM, Diagnosed Incident Cases of CC by HPV Status, Women, Ages ≥18 Years, N, 2020
Table 6: Treatment Guidelines for CC
Table 7: Top 10 Deals by Value, 2018-21
Table 8: CC Market - Global Drivers and Barriers, 2020-30
Table 9: Key Events Impacting Sales for CC in the US, 2020-30
Table 10: CC Market - Drivers and Barriers in the US, 2020-30
Table 11: Key Events Impacting Sales for CC in the 5EU, 2020-30
Table 12: CC Market - Drivers and Barriers in the 5EU, 2020-30
Table 13: Key Events Impacting Sales for CC in Japan, 2020-30
Table 14: CC Market - Drivers and Barriers in Japan, 2020-30
Table 15: Key Events Impacting Sales for CC in China, 2020-30
Table 16: CC Market - Drivers and Barriers in China, 2020-30
Table 17: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for CC in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in CC During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Locally Advanced CC During the Forecast Period
Figure 4: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the First-Line Treatment of Persistent, Recurrent, or Distally Metastatic CC During the Forecast Period
Figure 5: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Second-Line Treatment of Persistent, Recurrent, or Distally Metastatic CC During the Forecast Period
Figure 6: HPV Oncogenes Drive Malignant Transformation of Cervical Cells
Figure 7: 8MM, Diagnosed Incidence of CC (Cases per 100,000 population), Women, Ages ≥18 Years, 2010-30
Figure 8: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CC
Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CC by FIGO Stage at Diagnosis
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CC by Histology Subtypes
Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CC by Biomarkers and HPV Status
Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CC
Figure 13: 8MM, Diagnosed Incident Cases of CC, N, Women, Ages ≥18 Years, 2020
Figure 14: 8MM, Diagnosed Incident Cases of CC by Age, N, Women, 2020
Figure 15: 8MM, Diagnosed Incident Cases of CC by Histology Subtypes, N, Women, Ages ≥18 Years, 2020
Figure 16: 8MM, Diagnosed Incident Cases of CC by Biomarkers, N, Women, Ages ≥18 Years, 2020
Figure 17: 8MM, Five-Year Diagnosed Prevalent Cases of CC, N, Women, Ages ≥18 Years, 2020
Figure 18: Treatment Paradigm for CC
Figure 19: Unmet Needs and Opportunities in CC
Figure 20: Overview of the Development Pipeline in CC
Figure 21: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for CC in the 8MM During the Forecast Period
Figure 22: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC, Platinum Chemoradiation for the Treatment of Locally Advanced Disease
Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC, Avastin + Chemotherapy for Treatment of Persistent, Recurrent, or Distally Metastatic Disease - First Line
Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC, Keytruda for Treatment of Persistent, Recurrent, or Distally Metastatic Disease - Second Line
Figure 25: Analysis of the Company Portfolio Gap in CC During the Forecast Period
Figure 26: Global (8MM) Sales Forecast by Country for CC in 2020 and 2030
Figure 27: Sales Forecast by Class for CC in the US in 2020 and 2030
Figure 28: Sales Forecast by Class for CC in the 5EU in 2020 and 2030
Figure 29: Sales Forecast by Class for CC in Japan in 2020 and 2030
Figure 30: Sales Forecast by Class for CC in China in 2020 and 2030

$10,995
$21,990
$32,985

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings